Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Ioannis P Trontzas3rd Department of Medicine, 'Sotiria' Hospital of Respiratory Diseases, National and Kapodistrian University of Athens, 152 Mesogion Ave., 11527 Athens, Greece.
Ioanna-Evdokia GalaniLaboratory of Immunology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 4 Soranou Ephessiou Street, 11527 Athens, Greece.ORCID 0000-0002-0965-3863
Emmanouil Panagiotou3rd Department of Medicine, 'Sotiria' Hospital of Respiratory Diseases, National and Kapodistrian University of Athens, 152 Mesogion Ave., 11527 Athens, Greece.ORCID 0000-0002-4243-0434
Efthymia TheofaniLaboratory of Immunology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 4 Soranou Ephessiou Street, 11527 Athens, Greece.ORCID 0000-0003-3053-8197
Anastasia Georganta3rd Department of Medicine, 'Sotiria' Hospital of Respiratory Diseases, National and Kapodistrian University of Athens, 152 Mesogion Ave., 11527 Athens, Greece.
Konstantinos G Kyriakoulis3rd Department of Medicine, 'Sotiria' Hospital of Respiratory Diseases, National and Kapodistrian University of Athens, 152 Mesogion Ave., 11527 Athens, Greece.ORCID 0000-0001-8986-2704
Anastasia PalaiologouDivision of Pharmacology-Pharmacotechnology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 4 Soranou Ephessiou Street, 11527 Athens, Greece.
Ioannis Vathiotis3rd Department of Medicine, 'Sotiria' Hospital of Respiratory Diseases, National and Kapodistrian University of Athens, 152 Mesogion Ave., 11527 Athens, Greece.ORCID 0000-0002-1772-5986
Constantin TamvakopoulosDivision of Pharmacology-Pharmacotechnology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 4 Soranou Ephessiou Street, 11527 Athens, Greece.
Evangelos AndreakosLaboratory of Immunology, Center for Clinical, Experimental Surgery and Translational Research, Biomedical Research Foundation of the Academy of Athens (BRFAA), 4 Soranou Ephessiou Street, 11527 Athens, Greece.ORCID 0000-0001-5536-1661
Konstantinos N Syrigos3rd Department of Medicine, 'Sotiria' Hospital of Respiratory Diseases, National and Kapodistrian University of Athens, 152 Mesogion Ave., 11527 Athens, Greece.
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
PubMed holds no abstract for this paper.
Indexed as
complement protein C4CRPIL-6immunotherapynon-small cell lung cancerperipheral blood immune markers
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
In-Treatment Kinetics of Peripheral Blood Immune Markers in PD-L1 High Non-Small Cell Lung Cancer and Prognostic Relevance for Immunotherapy Outcomes. · full record | OpenQuestion